BioMaxima S.A.

BMX PW

BMX PWBioMaxima S.A.

WARSAW

17.00

PLN

-0.40

(-2.30%)

0.09EPS Dil.

188.89P/E

68.00MMarket Cap

Upgrade to Unlock Non-US CompaniesTo view real-time data and analysis of companies outside of the United States, upgrade your account to our premium subscription.

Upgrade

Ex-Dividend Date

June 16

Held by Insiders

27.92%

Use logarithmic scale

	2011 Y	2012 Y	2013 Y	2014 Y	2015 Y	2016 Y	2017 Y	2018 Y	2019 Y	2020 Y	2021 Y	2022 Y	2023 Y	TTM
Revenue per Share	5.14	6.19	6.9	6.72	7.23	7.23	8.47	8.26	8.17	14.92	18.31	33.25	10.84	11.24
Basic EPS, GAAP	0.49	0.45	0.43	0.15	0.48	0.33	0.22	-0.13	- -	1.78	2.37	6.68	0.14	0.09
Free Cash Flow per Basic Share	-1.88	-2.64	-0.22	0.09	0.65	0.12	-0.67	-8.77	0.44	0.05	-1.07	6.28	0.37	1.64
Dividend per Share	- -	- -	- -	- -	0.1	0.16	0.1	- -	- -	- -	0.25	0.45	0.49	- -
Book Value per Share	1.49	1.45	1.43	1.16	1.49	1.38	1.13	0.82	0.87	2.6	3.83	9.28	8.83	8.85
Tangible Book Value per Share	3.59	3.67	3.66	4.05	4.62	4.07	4.29	4.19	4.01	5.57	6.64	12.54	11.11	11.13
Basic Weighted Avg Shares	2	3	3	3	3	4	4	4	4	4	4	4	4	4
Sales/Revenue/Turnover	10	19	21	20	22	27	32	31	30	62	79	144	47	47
Operating Margin (%)	12.66	9.63	8.07	3.12	7.96	5.3	3.43	0.16	2.54	15.64	17.19	24.23	-0.51	1.04
Depreciation Expense	1	1	2	2	2	2	2	1	2	2	2	2	2	3
Net Income, GAAP	1	1	1	- -	1	1	1	- -	- -	7	10	29	1	- -
Effective Tax Rate (%)	17.25	19.58	15.59	4.47	13.7	11.98	9.53	- -	92.29	16.15	19.82	19.47	- -	- -
Profit Margin (%)	9.52	7.31	6.3	2.23	6.62	4.55	2.55	-1.56	-0.04	11.95	12.95	20.08	1.25	0.76
Working Capital	3	7	8	7	11	8	9	-1	6	15	16	25	12	13
LT Debt	2	2	4	2	4	1	2	7	6	8	9	4	9	10
Total Equity	8	13	14	14	16	17	17	17	16	26	29	52	47	47
Return on Invested Capital (%)	10.6	10.03	7.57	3.07	7.6	6.18	4.51	- -	0.19	23.76	25.41	53.23	- -	- -
Return on Capital (%)	20.33	21.32	16.26	7.08	18.4	15.52	12.12	- -	0.02	40.11	36.76	74.89	- -	- -
Return on Common Equity (%)	35.56	36.89	30.09	11.54	36.19	25.39	17.22	-13.29	-0.43	101.83	73.73	104.91	1.55	0.92

Capital Structure

•

in mil. unless spec.

Working Capital

•

in mil. unless spec.

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)	10 years	5 years	1 year
Sales/Revenue/Turnover	18.62%	28.76%	-67.48%
Net Income, GAAP	-5,465.52%	-10,919.93%	-97.97%
Free Cash Flow	-226.99%	-649.49%	-94.14%
Total Cash Common Dividend	- -	- -	7.65%
Total Equity	15.36%	27.42%	-10.45%

Growth Rates

•

in mil. unless spec.

Quarterly Revenue

•

in mil. unless spec.

Quarterly Earnings Per Share

•

in mil. unless spec.

Quarterly Dividends Per Share

•

in mil. unless spec.

Company Description

Full Time Employees: 122
Sector: Healthcare
Industry: Diagnostics & Research
Address: ul. Vetterów 5 Lublin Poland 20-277
Website: www.biomaxima.com
Business: BioMaxima S.A. manufactures and distributes microbiological media, reagents, and equipment for in vitro diagnostics in Poland. Its primary products include analyzers and diagnostic reagents for testing the biochemical parameters of blood and other body fluids; systems for the determination of drug resistance of microorganisms; quick diagnostic tests for detecting infectious diseases, cancer markers, heart attack markers, and addictive substances and readers; urine analysis systems; hematology analyzers and reagents; ionselective analyzers and reagents; reagents and immunological analyzers of cardiac markers; glucometers for professional use; and analyzers for gasometric tests and critical blood parameters tests. The company also provides surfaces and air controls; antibiotics discs and MIC strips; and chromogenic, dehydrated, and prepared culture media; additives and supplements for media; microbank microorganism storage systems; and veterinary products. In addition, it engages in the devices for microbiological analysis; molecular biology products, including media for inactivating and transporting samples; and training activities. The company supplies its products to approximately 1,800 laboratories in Poland, as well as exports in the international markets. BioMaxima S.A. was founded in 1997 and is headquartered in Lublin, Poland.

	Sep'23	Dec'23	Mar'24
ST Debt	3	4	3
LT Borrowings	5	9	9
LT Finance Leases	- -	- -	1
Preferred Equity and Hybrid Capital	- -	- -	- -
Shares Outstanding	4	4	4
Market Capitalization	77	69	51

	2011 Y	2012 Y	2013 Y	2014 Y	2015 Y	2016 Y	2017 Y	2018 Y	2019 Y	2020 Y	2021 Y	2022 Y	2023 Y	TTM
Revenue per Share	5.14	6.19	6.9	6.72	7.23	7.23	8.47	8.26	8.17	14.92	18.31	33.25	10.84	11.24
Basic EPS, GAAP	0.49	0.45	0.43	0.15	0.48	0.33	0.22	-0.13	- -	1.78	2.37	6.68	0.14	0.09
Free Cash Flow per Basic Share	-1.88	-2.64	-0.22	0.09	0.65	0.12	-0.67	-8.77	0.44	0.05	-1.07	6.28	0.37	1.64
Dividend per Share	- -	- -	- -	- -	0.1	0.16	0.1	- -	- -	- -	0.25	0.45	0.49	- -
Book Value per Share	1.49	1.45	1.43	1.16	1.49	1.38	1.13	0.82	0.87	2.6	3.83	9.28	8.83	8.85
Tangible Book Value per Share	3.59	3.67	3.66	4.05	4.62	4.07	4.29	4.19	4.01	5.57	6.64	12.54	11.11	11.13
Basic Weighted Avg Shares	2	3	3	3	3	4	4	4	4	4	4	4	4	4
Sales/Revenue/Turnover	10	19	21	20	22	27	32	31	30	62	79	144	47	47
Operating Margin (%)	12.66	9.63	8.07	3.12	7.96	5.3	3.43	0.16	2.54	15.64	17.19	24.23	-0.51	1.04
Depreciation Expense	1	1	2	2	2	2	2	1	2	2	2	2	2	3
Net Income, GAAP	1	1	1	- -	1	1	1	- -	- -	7	10	29	1	- -
Effective Tax Rate (%)	17.25	19.58	15.59	4.47	13.7	11.98	9.53	- -	92.29	16.15	19.82	19.47	- -	- -
Profit Margin (%)	9.52	7.31	6.3	2.23	6.62	4.55	2.55	-1.56	-0.04	11.95	12.95	20.08	1.25	0.76
Working Capital	3	7	8	7	11	8	9	-1	6	15	16	25	12	13
LT Debt	2	2	4	2	4	1	2	7	6	8	9	4	9	10
Total Equity	8	13	14	14	16	17	17	17	16	26	29	52	47	47
Return on Invested Capital (%)	10.6	10.03	7.57	3.07	7.6	6.18	4.51	- -	0.19	23.76	25.41	53.23	- -	- -
Return on Capital (%)	20.33	21.32	16.26	7.08	18.4	15.52	12.12	- -	0.02	40.11	36.76	74.89	- -	- -
Return on Common Equity (%)	35.56	36.89	30.09	11.54	36.19	25.39	17.22	-13.29	-0.43	101.83	73.73	104.91	1.55	0.92

	Sep'23	Dec'23	Mar'24
Total Current Assets	22	23	24
Accounts Receivable, Net	7	6	6
Cash, Cash Equivalents & STI	1	2	1
Inventories	14	13	13
Total Current Liabilities	10	10	10
Payables & Accruals	4	3	4
ST Debt	3	4	3
Deferred Revenue	- -	- -	- -

Year	Q1	Q2	Q3	Q4	FY
2022	- -	- -	0.46	- -	0.45
2023	- -	- -	- -	- -	0.49
2024	- -	- -	- -	- -	- -

Year	Q1	Q2	Q3	Q4	FY
2022	5.6	0.8	0.22	0.07	6.68
2023	0.11	0.09	-0.09	0.02	0.14
2024	0.06	- -	- -	- -	- -